MariTide: Risks & Legal Status
Important safety information, risks, and regulatory status
📌TL;DR
- •7 risk categories identified
- •0 high-severity risks
- •Legal status varies by country (4 countries listed)
Risk Assessment
MariTide is not approved by any regulatory authority. Phase 2 completed; Phase 3 MARITIME program initiated. Full safety profile not established.
The GLP-1 receptor agonist component carries the class warning for thyroid C-cell tumors. Contraindicated in patients with MTC or MEN2.
As an antibody-based therapeutic, MariTide may elicit anti-drug antibodies that could affect efficacy or safety over long-term use. Immunogenicity data not fully disclosed.
GI adverse events are the most common side effects, consistent with GLP-1 class. Most are mild to moderate.
The 21-day half-life means adverse effects may persist longer than with weekly or daily therapies if they occur.
GLP-1 receptor agonists are associated with pancreatitis risk.
Approximately 20% weight loss at 52 weeks increases the risk of cholelithiasis and cholecystitis.
⚠️Important Warnings
- •INVESTIGATIONAL AGENT: MariTide is not approved by any regulatory authority. It should only be used within approved clinical trials.
- •EXPECTED GLP-1 CLASS WARNING: MariTide is expected to carry the thyroid C-cell tumor warning. Do not use in patients with MTC or MEN2 history.
- •IMMUNOGENICITY: As an antibody-based therapeutic, MariTide may elicit anti-drug antibodies. Long-term immunogenicity data are limited.
- •GI adverse events are common, consistent with GLP-1 class. The 21-day half-life means effects may persist longer between doses.
- •Do not use during pregnancy. GLP-1 receptor agonists should be discontinued before planned conception.
- •No cardiovascular outcomes data are available. Long-term cardiovascular safety has not been established.
Legal Status by Country
| Country | Status | Notes |
|---|---|---|
| United States | Investigational | Phase 3 MARITIME program initiated. Not FDA-approved. |
| European Union | Investigational | Not EMA-approved. Regulatory pathway anticipated following Phase 3. |
| United Kingdom | Investigational | Not MHRA-approved. No regulatory submission. |
| Canada | Investigational | Not Health Canada-approved. No regulatory submission. |
Community Risk Discussions
See how the community discusses and manages these risks in practice.
0View community protocolsCritical Safety Information#
MariTide is an investigational antibody-peptide conjugate currently in Phase 3 development. Safety data are derived from Phase 1 and Phase 2 trials enrolling 592 participants with a maximum treatment duration of 52 weeks. As a novel molecular format (antibody-peptide conjugate), MariTide carries both GLP-1 class risks and antibody-specific considerations.
Investigational Status#
MariTide is in mid-stage development:
- Phase 2: Completed in 592 participants (52 weeks); published in NEJM
- Phase 3 MARITIME: Initiated; 72-week studies underway
- NDA: Not filed; regulatory approval pending Phase 3 results
- SC only: Monthly subcutaneous injection
GLP-1 Agonist Class Risks#
Thyroid C-Cell Tumors#
GLP-1 receptor agonists carry a class-wide boxed warning. MariTide is expected to carry similar warnings for MTC/MEN2.
Pancreatitis#
GLP-1 agonists have been associated with pancreatitis risk.
Gallbladder Disease#
The ~20% weight loss at 52 weeks increases gallstone risk.
Acute Kidney Injury#
GI-related dehydration may contribute to AKI risk.
Antibody-Specific Risks#
Immunogenicity#
MariTide's antibody component may elicit anti-drug antibodies (ADAs):
- ADAs could reduce efficacy by neutralizing the drug
- ADAs could cause hypersensitivity reactions
- Long-term immunogenicity data are limited
- Immunogenicity monitoring is standard in Phase 3 antibody trials
Long Half-Life#
The ~21-day half-life has implications for both benefits and risks:
- Benefit: Monthly dosing convenience
- Risk: Adverse effects, once present, may take longer to resolve
- Risk: Drug cannot be quickly "washed out" if adverse reactions occur
- Risk: Drug-drug interactions may have prolonged duration
Injection Volume and Site Reactions#
Large-molecule antibody therapeutics typically require larger injection volumes than peptide drugs, which may affect injection site tolerability.
Safety Database#
| Parameter | Current Data |
|---|---|
| Phase 1 patients | Small (exact N in Nature Metabolism) |
| Phase 2 patients | 592 |
| Maximum treatment duration | 52 weeks |
| Phase 3 program | MARITIME (72 weeks, underway) |
| CV outcomes data | None |
| Immunogenicity data | Not fully disclosed |
Regulatory and Legal Status#
| Jurisdiction | Status | Notes |
|---|---|---|
| United States (FDA) | Investigational | Phase 3 MARITIME initiated |
| European Union (EMA) | Investigational | No regulatory submission |
| United Kingdom (MHRA) | Investigational | No regulatory submission |
| Canada (Health Canada) | Investigational | No regulatory submission |
At-Risk Populations#
Patients with MTC or MEN2 History#
Expected absolute contraindication.
Pregnant and Breastfeeding Women#
GLP-1 receptor agonists carry pregnancy risks.
Patients with Antibody Sensitivity#
Patients with history of hypersensitivity to monoclonal antibody therapeutics.
Patients with Severe GI Disease#
GI adverse events may be poorly tolerated.
Patients on Insulin#
GLP-1 agonism may increase hypoglycemia risk with insulin.
Risk Mitigation#
- Use only within approved clinical trials
- Screen for MTC/MEN2 history
- Monitor for immunogenicity per trial protocol
- Follow dose escalation schedule
- Maintain adequate hydration
- Monitor for pancreatitis and gallbladder symptoms
- Adjust insulin doses when initiating treatment
- Be aware that the long half-life means effects persist weeks after dosing
Related Reading#
Frequently Asked Questions About MariTide
Explore Further
Medical Disclaimer
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.